What West Pharmaceutical Services's FY2025 10-K says: 11 signals
West Pharmaceutical Services filed its latest 10-K with the SEC on Feb 17, 2026. It discusses carbon commitment, compliance burden and cybersecurity incident.
Public (WST)Plastics Manufacturing10,000+ employeeswestpharma.comLinkedIn
- Filed
- Feb 17, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 10
What West Pharmaceutical Services's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 11 signals
Facing market share risk from customer shift to oral GLP-1s away from injectables
The company's business, which is highly dependent on injectable drug delivery systems for products like GLP-1s, is directly threatened by the potential industry shift to oral medications.
Navigating dynamic compliance environment, citing EU Deforestation Regulation
In 2025, the company focused on managing increased requirements and uncertainty from new regulations like the EU Deforestation Regulation.
West Pharma has established a cross-functional team led by its General Counsel to advance strategic priorities including a GHG reduction strategy, developing a sustainable supply chain, and reducing waste.
Company maintains an extensive network of security controls in response to cyber threats
West Pharma acknowledges it is a target for cyberattacks and is actively investing in technical controls, policy enforcement, and monitoring systems.
Launching climate and GHG reduction strategy with focus on renewable energy
The company has established a long-term strategic priority to create a greenhouse gas (GHG) reduction strategy, which includes incorporating renewable energy and lowering absolute emissions.
Facing increased pricing pressure as customers focus on total cost
The basis of competition is shifting from primarily product performance to include total cost, driven by aggressive cost-cutting from pharmaceutical company customers.
International sales grew to 56.7% of consolidated net sales in 2025
With over half of its revenue generated internationally, the company faces significant complexity in managing currency fluctuations, tariffs, and global supply chains.
56.7%
percentage of consolidated net sales from outside of the U.S. in 2025
Advancing sustainability strategy to meet new regulations like the EU Deforestation Regulation
The company is actively building its sustainability framework to address new compliance requirements and strategic priorities, including GHG reduction and creating a more responsible supply chain.
GHG reduction
Acknowledges its systems 'have... become the target of cyberattacks'
The company's disclosure that its systems have been targeted by cyberattacks in the past suggests potential vulnerabilities or a need to evaluate the effectiveness of current security measures.
Facing potential reduction in sales due to raw material shortages amid global economic conditions
The company identifies raw material shortages as a specific risk that could negatively affect sales.
Showing 10 of 11 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track West Pharmaceutical Services with the Signal API
One POST /v1/companies/enrich call with westpharma.com returns West Pharmaceutical Services 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"westpharma.com","signal_types":["sec-10k"],"limit":20}'Questions about West Pharmaceutical Services 10-K
When did West Pharmaceutical Services file its latest 10-K?
What does West Pharmaceutical Services's latest 10-K say about market share loss?
Where can I find West Pharmaceutical Services's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .